HER2, HER3, and TROP2: An Update on Novel Treatments for Key Targets

Download these slides from a live symposium to learn more about targeting HER2, HER3, and TROP2 with antibody-drug conjugates in breast cancer.

Aditya Bardia, MD, MPH Released: April 8, 2022

Download these slides from a live symposium to learn more about targeting HER2 and TROP2 with antibody-drug conjugates in gastrointestinal cancers.

Yelena Y. Janjigian, MD Released: April 8, 2022

Download these slides from a live symposium to learn more about targeting HER2, HER3, and TROP2 with antibody-drug conjugates in non-small cell lung cancer.

Sandip P. Patel, MD Released: April 8, 2022

In this on-demand webcast from a recent AACR satellite symposium, expert faculty highlight the latest evidence on the optimal use of HER2, HER3, and TROP2 antibody–drug conjugates in breast, gastrointestinal, and lung cancers.

Aditya Bardia, MD, MPH Yelena Y. Janjigian, MD Sandip P. Patel, MD Physicians: maximum of 2.0 AMA PRA Category 1 Credits™ Released: May 11, 2022 Expired: May 10, 2023

Commentary by physician experts in breast, gastrointestinal, and lung cancers on key takeaways from a live symposium on HER2-, HER3-, and TROP2-targeted therapies and treatment approaches for patients.

Aditya Bardia, MD, MPH
Program Director Yelena Y. Janjigian, MD Sandip P. Patel, MD Released: June 8, 2022